Show simple item record

dc.contributor.authorBates, Ruth L.
dc.contributor.authorPayne, Sarah J.
dc.contributor.authorDrury, S.L.
dc.contributor.authorNelson, Paul N.
dc.contributor.authorIsenberg, D.A.
dc.contributor.authorMurphy, John J.
dc.contributor.authorFrampton, Geoffrey
dc.date.accessioned2007-11-19T12:46:03Z
dc.date.available2007-11-19T12:46:03Z
dc.date.issued2003
dc.identifier.citationLupus 2003, 12(8): 617-622
dc.identifier.issn0961-2033
dc.identifier.pmid12945721
dc.identifier.doi10.1191/0961203303lu436oa
dc.identifier.urihttp://hdl.handle.net/2436/14650
dc.descriptionMetadata record only
dc.description.abstractWe have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodies in patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodies as compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus.
dc.language.isoen
dc.publisherSAGE Publications
dc.relation.urlhttp://direct.bl.uk/bld/PlaceOrder.do?UIN=136076849&ETOC=RN&from=searchenginehttp://lup.sagepub.com/cgi/content/abstract/12/8/617
dc.subjectSystemic lupus erythematosus
dc.subjectAutoantigen
dc.subjectSLE
dc.subjectAnti-PAI-1
dc.titleThe prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.
dc.typeJournal article
dc.format.digYES
html.description.abstractWe have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodies in patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodies as compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus.


This item appears in the following Collection(s)

Show simple item record